Every report we've published, newest first.
Sadot Group is running premarket after a July 16 8-K revealed a $350K settlement that dismisses the Helena lawsuit and terminates the equity line — pulling a dilution pipe off a sub-1M float.
Southland Holdings gapped over 50% pre-market after an Aecon-led consortium — with Southland's subsidiary holding a third — won a C$815M Winnipeg sewage plant contract. Tight float plus real news; here's the bracket.
DXST ripped premarket on no news, churning its tiny float roughly ten times before the open — but the tape is already back below VWAP, and the July 14 EGM put a 900M-share authorization on the table.
GrowHub signed its definitive merger agreement with Korean battery-materials maker EnChem, and the stock is gapping hard premarket. The catalyst is real — but it's confirmation of a May term sheet, and the deal can terminate if Nasdaq's pending delisting determination sticks.
Jet.AI's morning update pitched $10 per share in stock and cash from a $300M+ reverse takeover — the tape spiked to the low $7s and faded to $5. The gap is the market pricing a non-binding LOI with an unnamed counterparty.
VivoSim Labs ripped from 52-week lows on a $5M Eli Lilly milestone payment that exceeds its entire market cap — but the premarket tape already faded from the mid-$3s to below $2, and the ATM is armed.
NextCure roughly quadrupled in Tuesday's premarket after announcing an all-stock merger with Avere Therapeutics — an ex-Akero team, an oral once-weekly IL-23 drug, and $320M in concurrent financing. The stub's value hinges on net cash at close.
SHPH is ripping premarket with zero news behind it — just a sub-600K float, a fresh 10-for-1 reverse split, and a Dogecoin merger whose convertible paper is multiples of the entire tradable supply.
Q32 Bio's 36-week alopecia data hit clean and the sub-10M float repriced violently premarket — but a $300M shelf filed two weeks before the readout says supply may be next.
Pulsenmore spiked premarket on its selection to lead a $1M Israeli healthcare AI project — but a 3.1M-share resale registration went effective one trading day earlier, and the last spike round-tripped in under three weeks.
Global Mofy AI is the top premarket gapper with no company news behind it — a China small-cap frenzy hit a 1.68M post-split float, and Thursday's 100x volume spike at the 52-week low was the tell.
A Malaysian hotpot chain announced a $50M data center infrastructure maintenance agreement at 8:15 AM ET, and its 4.1M-share float turned over several times before the open. Here's the bracket and what the press release didn't say.
TDTH gapped into the mid-$3s premarket on Tuesday after Monday's announcement that its founder will swap $8M of debt for 901M restricted Class B shares — with the shareholder vote landing tomorrow and an ADS termination on July 16.
KIDZ doubled Monday morning on a self-announced award and the KIDZBot unveil — but the June 29 S-1 registers 151 million shares of forward supply under a Chardan equity line, against a float barely above a million.
Apple ripped nearly 5% Thursday on reports of a 10-million-unit foldable iPhone order — but the same two weeks brought a margin-driven selloff, a Supreme Court showdown, and a valuation stretched well past its five-year norm.
AHMA jumps 15% with heavy volume, but traders need perspective — this Dubai travel stock peaked at $39.50 in February and we're still 95% below that high.
SOBR Safe's 123% spike reveals the mechanics of a failing alcohol tech company becoming a Clean World Ventures green energy shell, with existing shareholders diluted to 2% ownership.
Global Engine Group rockets on AI-satellite infrastructure deal with Angkasa-X, yet investors buying a company racing against an October 26 Nasdaq delisting deadline.
Ernexa drops breakthrough preclinical data showing complete tumor elimination, but traders need to understand the dilution mechanics and timing risks behind this biotech moonshot.
EVC explodes 73% pre-market after reporting 114% revenue growth driven by 204% surge in advertising technology services, while positioning for massive political advertising cycle in 2026.
AHMA explodes 62% pre-market on 17x normal volume, but UAE tourism exposure and dual-class share structure create classic small-cap risk-reward setup.
GlucoTrack surges 37% pre-market as peer-reviewed diabetes monitor study publication builds momentum ahead of critical FDA filing expected within 4-8 weeks.
Backblaze crushed Q1 earnings with a shocking $0.04 EPS versus -$0.11 expected, yet Wall Street yawned. The disconnect tells a story about small-cap cloud infrastructure that traders need to understand.
DGXX explodes 47% pre-market after announcing a $1.1B AI data center deal with Cerebras Systems, validating the miner-to-AI infrastructure pivot with institutional-grade revenue visibility.
SDOT exploded 109% on a simple compliance filing, but the real story is a 125x increase in authorized shares and guaranteed dilution ahead.
Cellectar Biosciences erupts pre-market after announcing massive oversubscribed financing and compelling 12-month Waldenstrom macroglobulinemia data that strengthens FDA filing prospects.
Rectitude Holdings surged 47% pre-market as traders digest the mechanics of its Bitcoin treasury strategy funded by a standby equity agreement with crypto veterans.
RCT exploded 114% pre-market on a Saudi licensing deal, but the celebration masks a deeper story of chronic dilution and unsustainable cash burn that licensing agreements won't fix.
RMSG just doubled overnight on massive volume while everyone focuses on Nasdaq compliance issues. The tape suggests smart money sees opportunity in the distress.
AIXI rockets 51% pre-market as the Apple patent momentum trade reignites, but delisting risk, a wrecked balance sheet, and micro-cap mechanics make this one of the most dangerous tickers on the board.
RAYA rockets over 100% pre-market after disclosing a $400K offshore private placement at $0.08 per share while running a $20M ATM facility — textbook small-cap volatility meets dilution mechanics.
CREG surges on no news, but the filing history reveals a dilution machine with questionable business fundamentals — here's what the documents actually show.
GLMD explodes 88% higher premarket after announcing breakthrough brain-penetrating formulation of Aramchol, potentially expanding from NASH treatment into massive CNS disease markets.
ONCO jumps 38% pre-market after Realbotix delivered its first AI-equipped humanoid robot to Ericsson, but the real story is massive shareholder dilution from a pending acquisition that could give existing investors as little as 10% of the combined company.
QNCX doubles in pre-market on no fresh news, riding biotech momentum despite failed Phase 3 trials and ongoing strategic review — a high-risk momentum play with thin float dynamics.
Beasley Broadcast explodes higher on earnings day as debt restructuring progress and better-than-expected Q4 results trigger massive short squeeze.
OMEX rockets 162% pre-market on a $1B merger deal with American Ocean Minerals, but the required 25-for-1 reverse stock split reveals the dilution reality behind the billion-dollar headlines.
Heritage Distilling's complete pivot to IP Strategy Holdings caught the market flat-footed, with the stock now up 61% pre-market as traders scramble to understand the Story Protocol validator play.
SILO explodes 62% on European PTSD patent approval, but its history of dilutive offerings and massive cash burn create a complex risk-reward setup for momentum traders.
Huachen AI Parking explodes on news it got more time to fix its sub-dollar problem, but this looks like desperation buying on a dilution machine with no real catalyst.
Cemtrex subsidiary Invocon lands Phase I Navy SBIR contract for mine warfare technology, validating the company's aerospace pivot just months after completing its $7.06M acquisition.
Focus Universal rockets 109% pre-market on AI software claims, but traders should watch the float and fundamentals before chasing.
While traders chase the 24% pre-market pop, Moolec Science's real story lies buried in complex restructuring mechanics that Wall Street might have miscalculated.
Profusa soars 130% pre-market on PanOmics acquisition and Mayo Clinic partnership, but extreme dilution risk and 377% short interest tell a different story.
TMD Energy rocketed in pre-market trading as Middle East tensions spike oil prices, but beneath the geopolitical pop lies a classic post-IPO dilution story with razor-thin margins and troubling cash flow.
While BCG surged 30% on earnings that showed its first full-year profit as a public company, the celebration might be premature given hidden dilution risks and leverage concerns.
CYCN exploded 439% this morning on a $380M reverse merger with Korsana Biosciences, transforming a penny biotech shell into an institutional-backed Alzheimer's drug play.
ARTL exploded 163% overnight as clinical expansion into the $16.3B glaucoma market demonstrates the power of a diversified cannabinoid platform targeting multiple billion-dollar therapeutic verticals.
EEIQ delivered a textbook compliance squeeze, surging 134% on 140x normal volume as the company regained Nasdaq minimum bid requirements just days before their March 2 delisting deadline.
LNAI explodes 57% on $20M blood-brain barrier acquisition deal as traders position around today's NASDAQ delisting hearing outcome.
Real Messenger's massive Monday surge looks like classic penny stock manipulation as the company faces Nasdaq delisting after falling below $1 for 30 straight days.
Next Technology's spectacular collapse from $28 to $1.20 in three months reveals the brutal mechanics of dilution machines masquerading as bitcoin treasuries.
ITOC rockets 80% pre-market after announcing a $20M private placement at $0.20 per share, creating arbitrage dynamics and dilution risk for the beaten-down cancer treatment software play.
Eagle Nuclear explodes higher on sector momentum and permitting news, but small-cap uranium plays carry serious float expansion risks.
GoHealth surged 22% Monday after touching $1.31 all-time lows in early March, but the rally masks deeper structural problems from massive dilution and deteriorating fundamentals.
Robin Energy explodes 87% on surprise $3 tender offer, creating potential arbitrage play but highlighting the risks of a serial dilution machine.
ENvue Medical surges on Detroit hospital deal expanding its feeding tube navigation platform to 39 hospitals, but Series H preferred shares create 800% dilution overhang.
PAVS jumped 93% after ending its share dilution program with AGP, but the mechanics suggest this is temporary relief rather than a fundamental turnaround.
Powell Max caught fire on news of a $9M solar acquisition, but traders need to read between the lines on this micro-cap's cash-burning structure.
GMEX exploded 35% on its first commercial robotics order worth AU$4.2M — three times the company's market cap. Here's how the fitness-to-robotics transformation is playing out and what traders need to watch.
ZYBT bounced hard off March 2nd's close but the Chinese vet vaccine maker still trades 94% below its April 2025 peak amid ongoing dilution concerns.
AHMA's 73% surge on travel industry news masks serious governance restructuring and extreme valuations that suggest this momentum play carries significant risks.
UGRO ripped 74% to $3.79 in Sunday's pre-market session after a brutal 25:1 reverse split created massive mechanical pressure on what's now a minuscule 684K share float.
MGRX popped 116% on a $73M lawsuit against its former tech partner, but the damages sought are 11x the company's market cap—classic small-cap narrative engineering.
Agroz bounced 153% last Thursday on the Strait of Hormuz crisis, then gave back 27% Friday. Now trading at key support with a Nasdaq compliance deadline looming.
ANNA explodes 50% as Iran war drives energy crisis, but massive insider selling from controlling shareholders just before the rally raises serious red flags about sustainability.
AZTR rockets 92% on desperate biotech financing that could deliver either runway extension or massive dilution trap for retail traders.
Wetour Robotics' 57% surge Wednesday masks deeper questions about dilution risk and a pivot from struggling travel tech to unproven AI infrastructure.
Serina Therapeutics surged 76% on a $30M private placement deal, but the real story is in the warrant mechanics and potential $63M dilution structure.
Linkers Industries surges pre-market despite filing to dump up to 405 million shares into the market just days ago, raising questions about what traders aren't seeing.
China Natural Resources rockets on HooRii Technology acquisition announcement, but traders should watch the $37-40 million dilution event closely — the Physical AI story might be secondary to the balance sheet math.
EVTV's 46% rip on 8.3M volume tells the story of a desperation pivot gone right, but dilution demons still lurk in the shadows.
ARTL exploded 33% on glaucoma study news with 72x float volume, but the cash burn and dilution risks make this more squeeze than substance.
VNRX explodes 39% on breakthrough liquid biopsy claims, but massive volume and delisting pressures create a complex risk-reward setup.
LBGJ rockets 138% in pre-market but immediately begins fading from highs, exposing the mechanical nature of the move and underlying dilution risks.
AIM explodes 110% pre-market after securing final Japanese patent approval for Ampligen cancer combination therapy, but dilution risks loom from recent rights offering.
bioAffinity Technologies exploded 122% on March 13 earnings, then gave back gains as investors parsed the dilution-heavy reality behind the revenue surge.
UCAR explodes 67% pre-market on Thailand battery-truck news, but the skeptic's math reveals dilution risks that bulls are ignoring in this micro-cap momentum play.
LNAI exploded 160% pre-market Monday on classic squeeze mechanics, but this dying biotech's final spike before potential delisting represents everything dangerous about small-cap trading.
Meiwu Technology's shares exploded from $1.80 to $13.52 after announcing an AI-powered skincare R&D program, but recent dilution and pending shelf offerings cloud the momentum play.
ABCD ripped 18% pre-market on volume that doesn't match anything in the last 30 days. No PR. No earnings. So what moved it?
EFGH ran 40% in the first hour yesterday. By close, it was red. Here's what the filing told you at 7 AM that most people didn't read until it was too late.
Most small-cap FDA plays are lottery tickets. IJKL might actually have the structure to hold a move — if you understand the float dynamics.